BAT may Face Shareholder Lawsuits Due to Reynolds' $3.15 Billion Write-Down

Regulations by 2FIRSTS.ai
Jan.30.2024
BAT may Face Shareholder Lawsuits Due to Reynolds' $3.15 Billion Write-Down
BAT faces multiple shareholder lawsuits as a result of a $3.15 billion write-down of Reynolds Tobacco's iconic traditional cigarette brand.

According to a report by journalnow on January 29th, British American Tobacco (BAT) may face multiple shareholder lawsuits due to a $31.5 billion impairment on the iconic traditional cigarette brand of Reynolds Tobacco Company.

 

This write-down has triggered responses from at least five law firms, who are actively seeking potential lead plaintiffs. These investors allege that BAT made false statements and failed to disclose the risks associated with the write-down of high-end American cigarette brands.

 

In early December last year, BAT disclosed the devaluation of brands such as Xin Gang, Luo Tu, Beiermo, and American Natural Spirit, changing their value status from "indefinite" to "limited". As a result, the value lifespan of these four brands shifted from "permanent" to approximately 30 years, meaning until 2054.

 

At least five law firms are currently seeking potential lead plaintiffs for lawsuits that share a commonality: BAT failed to adequately disclose the risks it faced, leading to a near 9% drop in stock prices for investors after the devaluation announcement on December 6th.

 

Tadeu Marocco, CEO of BAT, mentioned BAT's vision of creating a "smoke-free world" and the impact of current macroeconomic obstacles on the combustible tobacco industry in the United States while explaining the impairment decision.

 

This devaluation is a clear indication of concerns over the rapid decline in traditional cigarette consumption in the United States. According to the data from the Centers for Disease Control and Prevention, approximately 11.5% of American adults were identified as smokers in 2021, marking a decrease from 20.9% in 2005.

 

Investor concerns indicate the pressure faced by BAT in building a strategy for smokeless nicotine and tobacco products. The executive changes at Reynolds Company have intensified the pressure for improving the performance of their traditional cigarette portfolio.

 

During the first half of the 2023 fiscal year, at the financial report briefing, Marloko clearly stated, "We are disappointed with the performance of our traditional cigarettes in the United States. Sustaining value creation in combustible products is crucial for our multi-category strategy in the US.

 

The potential litigation period for purchasers of publicly traded securities of BAT extends from February 9th to December 6th. This lawsuit will have implications for BAT and its current and former executives, potentially making them defendants in the litigation.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Haypp Group reported a 40% year-on-year increase in nicotine pouch volumes in the first quarter of 2026, with U.S. and U.K. volumes rising 123% and 102%, respectively. Haypp says around 97% of its consumer traffic is organic and that its Media & Insights business provides brand owners with on-site visibility, trial activation and consumer intelligence. For international tobacco companies, Haypp may be both a growth partner for modern oral products and a new source of channel leverage.
Special Report
May.22
Product | Geek Bar BURJ 80K Extends High-Puff Competition Into Hookah-Style DTL Use
Product | Geek Bar BURJ 80K Extends High-Puff Competition Into Hookah-Style DTL Use
2Firsts has noted that Geek Bar has added BURJ to its official product portfolio under the E-HOOKAH category. Public information shows that BURJ 80K is a hookah-style disposable vape featuring a 25ml e-liquid capacity, a 1500mAh battery, 0.4Ω dual coils and three operating modes: ECO, Regular and Pulse. According to publicly available product information, the device is rated for up to 80,000 puffs in ECO mode and uses a nicotine strength of 0.5% (5mg/ml).
Market
May.29
FDA Expands ENDS Market Access With First Authorization of Non-Tobacco and Non-Menthol Products
FDA Expands ENDS Market Access With First Authorization of Non-Tobacco and Non-Menthol Products
The U.S. Food and Drug Administration (FDA) announced on May 5, 2026 that it authorized the marketing of four Glas electronic nicotine delivery system (ENDS) products through the premarket tobacco product application (PMTA) pathway. The authorized products are Classic Menthol, Fresh Menthol, Gold and Sapphire pods, each containing 50mg/ml, or 5%, tobacco-derived nicotine.
May.06 by 2FIRSTS.ai
Capital Group Takes 5.61% Stake in KT&G, Joining Major Foreign Shareholders
Capital Group Takes 5.61% Stake in KT&G, Joining Major Foreign Shareholders
KT&G disclosed in a regulatory filing on Friday that Capital Research and Management Company, the investment management arm of Capital Group, had acquired a 5.61% stake through purchases made on April 22 and May 4. The move places Capital Group among KT&G’s prominent foreign shareholders, alongside BlackRock, First Eagle Investment Management and Singapore’s sovereign wealth fund GIC.
May.08 by 2FIRSTS.ai
FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches
FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches
The U.S. Food and Drug Administration issued guidance on May 8, 2026, titled “Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization.” The document describes FDA enforcement policies for certain electronic nicotine delivery system products and nicotine pouch products marketed without premarket authorization.
May.09 by 2FIRSTS.ai
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA CTP issued a May 7 statement on accelerating product review and improving PMTA efficiency, but did not push it via official X and newsletter until May 13, one day after FDA Commissioner Marty Makary’s resignation was confirmed. FDA has not explained the delay, and no public evidence links it directly to the leadership change. The timing is notable given CTP’s usual 24-hour distribution practice.
Special Report
May.14